CYDY

CytoDyn Inc. [CYDY] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

CYDY Stock Summary

In the News

CYDY Financial details

Company Rating
-
Market Cap
154.81M
Income
-55.65M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
12
Optionable
No
Shortable
Yes
Earnings
12 Apr 2024
P/E
-2.61
Forward P/E
-
PEG
0.3
P/S
-
P/B
-1.63
P/C
-
P/FCF
-10.38
Quick Ratio
0.02
Current Ratio
0.09
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.06
EPS next Y
-
EPS next Q
-
EPS this Y
-77.81%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-20%
-
-
-
-
SMA20
-
SMA50
-14.29%
SMA100
-11.11%
Inst Own
-
Inst Trans
-
ROA
-590%
ROE
65%
ROC
0.3%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-1%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.15-0.42
52W High
-
52W Low
-
RSI
56.81
Rel Volume
0.21
Avg Volume
2.98M
Volume
624.18K
Perf Week
7.44%
Perf Month
5.26%
Perf Quarter
-10.96%
Perf Half Y
-17.99%
-
-
-
-
Beta
0.188
-
-
Volatility
0.01%, 0.01%
Prev Close
3.34%
Price
0.26
Change
4%

Something similar

Top by Market Cap
LLY.SW
M&M.NS
TL0.DE
MSFT
MSF.DE
Same Sector
ALPHA.PA
NRIX
300601.SZ
WEED.TO
DIM.PA
Same Price Range
1708.HK
1941.HK
1965.HK
1058.HK
0789.HK
Similar Market Cap
WHOSX
BTMFX
GPACU
BSMR
GENL.L

Company Profile

Healthcare Biotechnology
  • Volume Average 2.98M
  • Market Capitalization 154.81M
  • Employee 12
  • CEO Dr. Jacob P. Lalezari M.D.
  • Headquarters Vancouver,WA,US
  • IPO Date 2006-12-13
  • Website https://www.cytodyn.com

CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (“COVID-19”). It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.